This invention relates to substituted thiazoles of formula I:
wherein: L is selected from the group consisting of -NHC(X)-, -C(X)NH-, -NHC(X)NH-, -C(X)-, -C(X)NH-alkylene- and -NHC(X)-alkylene-, where X is oxygen or sulfur; and Q is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclic and substituted heterocyclic, pharmaceutically acceptable salt thereof, pharmaceutical compositions containing them, and their use as VEGFR2 (vascular endothelial growth factor receptor 2) kinase inhibitors and in the treatment of diseases capable of treatment by a VEGFR2 kinase inhibitor, particularly cancer.
本发明涉及式I的取代
噻唑:其中:L选自由-NHC(X)-,-C(X)NH-,-NHC(X)NH-,-C(X)-,-C(X)NH-烷基-和-NHC(X)-烷基-的群,其中X为氧或
硫;Q选自烷基,取代烷基,芳基,取代芳基,杂芳基,取代杂芳基,环烷基,取代环烷基,杂环和取代杂环,其药学上可接受的盐,含有它们的制药组合物,以及它们作为V
EGFR2(血管内皮生长因子受体2)激酶
抑制剂和治疗能够通过V
EGFR2激酶
抑制剂治疗的疾病,特别是癌症的用途。